These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28096309)

  • 1. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.
    Marinozzi MC; Roumenina LT; Chauvet S; Hertig A; Bertrand D; Olagne J; Frimat M; Ulinski T; Deschênes G; Burtey S; Delahousse M; Moulin B; Legendre C; Frémeaux-Bacchi V; Le Quintrec M
    J Am Soc Nephrol; 2017 May; 28(5):1603-1613. PubMed ID: 28096309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-factor B autoantibody in dense deposit disease.
    Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
    Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.
    Wong EKS; Marchbank KJ; Lomax-Browne H; Pappworth IY; Denton H; Cooke K; Ward S; McLoughlin AC; Richardson G; Wilson V; Harris CL; Morgan BP; Hakobyan S; McAlinden P; Gale DP; Maxwell H; Christian M; Malcomson R; Goodship THJ; Marks SD; Pickering MC; Kavanagh D; Cook HT; Johnson SA;
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1639-1651. PubMed ID: 34551983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
    Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
    Front Immunol; 2021; 12():690821. PubMed ID: 34177949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
    Gupta N; Wakefield DN; Clapp WL; Garin EH
    Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
    West CD; McAdams AJ
    Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined C3b and factor B autoantibodies and MPGN type II.
    Chen Q; Müller D; Rudolph B; Hartmann A; Kuwertz-Bröking E; Wu K; Kirschfink M; Skerka C; Zipfel PF
    N Engl J Med; 2011 Dec; 365(24):2340-2. PubMed ID: 22168663
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.
    Wang X; Van Lookeren Campagne M; Katschke KJ; Gullipalli D; Miwa T; Ueda Y; Wang Y; Palmer M; Xing G; Song WC
    J Am Soc Nephrol; 2018 Aug; 29(8):2053-2059. PubMed ID: 29895552
    [No Abstract]   [Full Text] [Related]  

  • 14. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
    Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
    Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor B and C4b2a Autoantibodies in C3 Glomerulopathy.
    Hauer JJ; Shao D; Zhang Y; Nester CM; Smith RJH
    Front Immunol; 2019; 10():668. PubMed ID: 31024533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy.
    Garam N; Prohászka Z; Szilágyi Á; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik-Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Romana Rysava ; Reiterova J; Saraga M; Tomáš Seeman ; Zieg J; Sládková E; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Csuka D
    Orphanet J Rare Dis; 2019 Nov; 14(1):247. PubMed ID: 31703608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-factor B antibodies in atypical hemolytic uremic syndrome.
    Khandelwal P; Nambiar S; Saini R; Saini S; Coshic P; Sinha A; Hari P; Palanichamy JK; Bagga A
    Pediatr Nephrol; 2024 Jun; 39(6):1909-1916. PubMed ID: 38252289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
    Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
    J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C3G and Ig-MPGN-treatment standard.
    Noris M; Remuzzi G
    Nephrol Dial Transplant; 2024 Jan; 39(2):202-214. PubMed ID: 37604793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.